These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 39395088)

  • 1. Recent advances and current status of gene therapy for epilepsy.
    Cai AJ; Gao K; Zhang F; Jiang YW
    World J Pediatr; 2024 Nov; 20(11):1115-1137. PubMed ID: 39395088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
    Laurent M; Geoffroy M; Pavani G; Guiraud S
    Cells; 2024 May; 13(10):. PubMed ID: 38786024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) as a Genetic Scalpel for the Treatment of Cancer: A Translational Narrative Review.
    Mondal R; Brahmbhatt N; Sandhu SK; Shah H; Vashi M; Gandhi SK; Patel P
    Cureus; 2023 Dec; 15(12):e50031. PubMed ID: 38186450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and Perspective of CRISPR-Cas9 Technology in Translational Medicine.
    Zheng R; Zhang L; Parvin R; Su L; Chi J; Shi K; Ye F; Huang X
    Adv Sci (Weinh); 2023 Sep; 10(25):e2300195. PubMed ID: 37356052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease.
    Hung SSC; McCaughey T; Swann O; Pébay A; Hewitt AW
    Prog Retin Eye Res; 2016 Jul; 53():1-20. PubMed ID: 27181583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
    Wang Y; Jiang H; Li M; Xu Z; Xu H; Chen Y; Chen K; Zheng W; Lin W; Liu Z; Lin Z; Zhang M
    Gene; 2024 Nov; 927():148733. PubMed ID: 38945310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
    Cheng X; Fan S; Wen C; Du X
    Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
    Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.
    Song Z; Tao Y; Liu Y; Li J
    Front Immunol; 2024; 15():1444437. PubMed ID: 39281673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in CRISPR/Cas9 Technology for in Vivo Translation.
    Çiçek YA; Luther DC; Kretzmann JA; Rotello VM
    Biol Pharm Bull; 2019; 42(3):304-311. PubMed ID: 30828060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.